Journal
JOURNAL OF BONE AND MINERAL RESEARCH
Volume 36, Issue 2, Pages 283-297Publisher
WILEY
DOI: 10.1002/jbmr.4177
Keywords
CRISPR-CAS9; INCOMPLETE PENETRANCE; RIBOSOMOPATHY; RPL13; SPONDYLOEPIMETAPHYSEAL DYSPLASIA; VARIABLE EXPRESSIVITY; ZEBRAFISH
Categories
Funding
- Academy of Finland [277843]
- Sigrid Juselius Foundation
- Folkhalsan Research Foundation
- Novo Nordisk Foundation [21322]
- Swedish Research Council [2603]
- Stockholm County Council
- Italian Ministry of Education, University and Research (MIUR) under the initiative Dipartimenti di Eccellenza (2018-2022)
- Bloodwise [12048]
- UK Medical Research Council [MC_U105161083]
- Wellcome Trust [100140]
- MRC
- Cambridge National Institute for Health Research Biomedical Research Centre
- Finnish Cultural Foundation
- HKH Princess Lovisa's foundation for child health care
- Sallskapet Barnavard in Stockholm
- MRC [MR/T012412/1, MC_U105161083] Funding Source: UKRI
Ask authors/readers for more resources
Spondyloepimetaphyseal dysplasias (SEMDs) are a group of heterogeneous disorders affecting the spine and long bone epiphyses and metaphyses. This study identifies RPL13 mutations causing incomplete dominant inheritance and variable skeletal phenotypes. Mutation-positive subjects demonstrated impaired ribosomal function, highlighting the role of eL13 in skeletogenesis.
Spondyloepimetaphyseal dysplasias (SEMDs) are a heterogeneous group of disorders with variable growth failure and skeletal impairments affecting the spine and long bone epiphyses and metaphyses. Here we report on four unrelated families with SEMD in which we identified two monoallelic missense variants and one monoallelic splice site variant inRPL13, encoding the ribosomal protein eL13. In two out of four families, we observed autosomal dominant inheritance with incomplete penetrance and variable clinical expressivity; the phenotypes of the mutation-positive subjects ranged from normal height with or without hip dysplasia to severe SEMD with severe short stature and marked skeletal dysplasia.In vitrostudies on patient-derived dermal fibroblasts harboringRPL13missense mutations demonstrated normal eL13 expression, with proper subcellular localization but reduced colocalization with eL28 (p< 0.001). Cellular functional defects in fibroblasts from mutation-positive subjects indicated a significant increase in the ratio of 60S subunits to 80S ribosomes (p= 0.007) and attenuated global translation (p= 0.017). In line with the human phenotype, ourrpl13mutant zebrafish model, generated by CRISPR-Cas9 editing, showed cartilage deformities at embryonic and juvenile stages. These findings extend the genetic spectrum ofRPL13mutations causing this novel human ribosomopathy with variable skeletal features. Our study underscores for the first time incomplete penetrance and broad phenotypic variability in SEMD-RPL13 type and confirms impaired ribosomal function. Furthermore, the newly generatedrpl13mutant zebrafish model corroborates the role of eL13 in skeletogenesis. (c) 2020 The Authors.Journal of Bone and Mineral Researchpublished by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)..
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available